 BOULDER, Colo.--BUSINESS WIRE--Edgewise Therapeutics, Inc. NASDAQ: EWTX, a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the pricing of its underwritten initial public offering of 11,000,000 shares of its common stock at a public offering price of 16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on March 26, 2021 under the ticker symbol EWTX 